This article is from the source 'bbc' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.

You can find the current article at its original source at http://www.bbc.co.uk/news/business-29797772

The article has changed 6 times. There is an RSS feed of changes available.

Version 2 Version 3
Asian shares trade lower ahead of Fed meeting Asian shares trade lower ahead of Fed meeting
(about 4 hours later)
Asian stocks are mostly falling ahead of the Federal Reserve meeting where policymakers are expected to make a decision on its stimulus programme. Asian stocks are mostly lower with traders looking ahead to the meeting of policymakers at the US Federal Reserve.
Most analysts expect the US central bank to end its monthly bond-buying programme and maintain its key interest rate at a record low. Most analysts expect the US central bank to end its monthly bond-buying programme and maintain its benchmark interest rate at a record low.
Japan's benchmark Nikkei lost 0.2% despite data showing September retail sales beat economist estimates. Japan's benchmark Nikkei closed down 0.4% despite data showing September retail sales beat economist estimates.
Australia, New Zealand and Singapore are all trading in negative territory. Australian and South Korean shares also ended trading in negative territory. In Hong Kong shares rose 1%.
Hong Kong stocks bucked the downward trend, rising 0.2% to 23,190 points at the open on Tuesday. In Shanghai shares were 1.7% higher.
The Fed has been looking to end its stimulus programme, also known as quantitative easing (QE), by gradually reducing the amount provided for its asset-purchase programme. The Federal Reserve has been looking to end its stimulus programme, also known as quantitative easing (QE), by gradually reducing the amount provided for its asset-purchase programme.
However, concerns over the withdrawal of the US stimulus has previously caused volatility in Asian stock markets.However, concerns over the withdrawal of the US stimulus has previously caused volatility in Asian stock markets.
That's because the Fed's programme helped money to flow into emerging market stocks, bonds and property in Asia despite structural weaknesses in their overall economies. That is because the Fed's programme helped money to flow into emerging market stocks, bonds and property in Asia despite structural weaknesses in their overall economies.
Stock moversStock movers
Shares in China's biggest train makers CSR and China CSR were suspended from trading in Hong Kong and Shanghai following reports the two companies are planning to merge. Shares in China's biggest train makers CSR and China CSR were suspended from trading in Hong Kong and Shanghai following reports the two companies were planning to merge.
According to the China Securities Journal, the two firms had set up working groups to discuss a possible merger which would help promote China's high-speed train technology overseas.According to the China Securities Journal, the two firms had set up working groups to discuss a possible merger which would help promote China's high-speed train technology overseas.
In Australia, shares of Bega Cheese fell by more than 2% after it said profit growth next year will "present a significant challenge". In Australia, shares of Bega Cheese fell as much as over 2% after it said profit growth next year would "present a significant challenge".
The company has been affected by Russian sanctions on western food imports and falling global dairy prices.The company has been affected by Russian sanctions on western food imports and falling global dairy prices.
Japanese pharmaceutical Takeda Pharmaceutical, however, got a lift on Tuesday after a US judge reduced a $9bn (£5.6bn) penalty to $36.8m over a diabetes drug. Japan's Takeda Pharmaceutical received a boost on Tuesday after a US judge reduced a $9bn (£5.6bn) penalty over a diabetes drug, to $36.8m .
Takeda, which jointly made the drug with US firm Eli Lilly, faces more than 2,900 lawsuits alleging the drugmakers failed to warn users the drug could increase their risk for bladder cancer.Takeda, which jointly made the drug with US firm Eli Lilly, faces more than 2,900 lawsuits alleging the drugmakers failed to warn users the drug could increase their risk for bladder cancer.
Its shares rose nearly 3% in Tokyo, outperforming the overall decline in the benchmark Nikkei. Its shares rose 1% in Tokyo, outperforming the overall decline in the benchmark Nikkei.